UW21002
OPEN TO ACCRUAL
PII Trial of ctDNA-Guided 2nd line Adjuvant Therapy for High Risk, Stage II-III, ER+ HER2- BC (DARE)
UW22102
OPEN TO ACCRUAL
RaPhLRR: PII Ribociclib + Endocrine Tx for Recurrent, Resected HR+ HER2- Breast Cancer
UW23027
OPEN TO ACCRUAL
PIII Adjuvant Camizestrant in ER+/HER2- Early Breast Cancer After 2+ yrs of standard ET
NRGBR009
OPEN TO ACCRUAL
Trial Evaluating Addition of Adjuvant Chemo to Ovarian Function Suppression + Endocrine Therapy
UW23102
OPEN TO ACCRUAL
Cambria-2: Adjuvant Endocrine-based Therapy of Camizestrant in ER+/HR2- Early BC